LOS ANGELES, CA--(Marketwired - Apr 15, 2014) - David Hoye has been appointed to the Board of Directors of SK3 Group, Inc. (OTC Pink: SKTO) (PINKSHEETS: SKTO). Hoye is co-founder of Berkeley Bio-Organic Research Laboratories, which was acquired in April of last year.
"I am honored to be asked to take this position," said Hoye. "Over the past year that my group has been working with SK3 Group, I have been very impressed with the skill, competence, and compassion for patients expressed by my new partners. It seems that we now have a perfect union of business and financial acumen combined with science and compassion. I could not have asked for a better situation when I first associated with SK3 Group, and being asked to take an increased role in the overall direction we will be taking as we pioneer this new sector is something that I cherish."
"We are very pleased to have David take an official position on the Board of Directors of our company," said Artemus Mayor, President of SK3 Group, Inc. "David's Berkeley Bio-Organic Research Laboratories was an early acquisition made by SK3 Group after entering the medical marijuana sector. As a result of his expertise, knowledge, and experience, we now have a rapidly expanding line of unique, industry-leading cannabis/hemp-based products and technology that will play an important role in this new sector of medicine. By taking an official position on the Board of SK3 Group, parent company of Berkeley Bio, David will help guide us through the many intricacies of this fascinating and beneficial emerging new world of business and healthcare."
"David's accomplishments in this world are legendary. His book, Cannabis Alchemy, published in 1972, has sold 100,000 copies and was the first scientific book on cannabis technology presented from a consumer's point of view. It introduced the cannabis culture to cannabidiol (CBD), cannabis oil, isomerization, extraction, resin separation, and refinement to pure THC. Amongst many other significant accomplishments, David opened the first new legal dispensary in San Francisco after the passage of Proposition 215, he and his wife Mary Ann founded and run a collective which treats dozens of cancer patients at no cost, and David was a co-founder of Berkeley Bio-Organic Research Laboratories, which has made several groundbreaking discoveries resulting in exciting and beneficial new cannabis/hemp-based healthcare products."
"David's achievements over nearly five decades in cannabis science have made him renowned in the world of cannabis culture," Mayor continued. "His experience, knowledge, and contacts in this arena will be of great benefit as we determine the best path to take in order to provide solid value to our shareholders, and the substantial healthcare benefits of this amazing medicinal plant to the patients who utilize our technology and products."
About SKTO
SK3 Group, Inc. is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 Group brings standardization and transparency to this rapidly growing segment of the alternative care field.
FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.